ANI Pharmaceuticals (NASDAQ:ANIP): $0.03 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 1.15. The value of trades done on upticks was $0.24 million, whereas, trades done on downticks were valued at $0.21 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.01 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.01 million. ANI Pharmaceuticals (NASDAQ:ANIP) fell $0.05 traded at $56.95, a change of -0.09% over the previous day. The stock is 4.8% for the week.
In an insider trading activity, The officer (Vice President, Operations), of Ani Pharmaceuticals Inc, Marken James G. had unloaded 3,500 shares at $43.26 per share in a transaction on December 18, 2015. The total value of transaction was $151,410. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 31.6% of ANI Pharmaceuticals shares according to the proxy statements. Institutional Investors own 49.99% of ANI Pharmaceuticals shares.
The company shares have dropped -8.73% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $73.54 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $51.88 and the 200 Day Moving Average price is recorded at $41.62. ANI Pharmaceuticals (NASDAQ:ANIP): The stock opened at $57.78 on Wednesday but the bulls could not build on the opening and the stock topped out at $57.91 for the day. The stock traded down to $55.92 during the day, due to lack of any buying support eventually closed down at $56.18 with a loss of -1.44% for the day. The stock had closed at $57.00 on the previous day. The total traded volume was 318,643 shares.
ANI Pharmaceuticals, Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Companys focused areas of product development include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products. The Companys branded products consist of Cortenema, Lithobid, Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone, Fluvoxamine Maleate, Hydrocortisone Enema, Methazolamide, Metoclopramide and Opium Tincture. The Companys markets include hormone and steroidal drugs, oncolytics, and narcotics and complex formulations, including extended release and combination products.